Otakar H.
- Country
- Czechia
- Department
- NA
Research Overview
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Study Evaluating Efficacy and Safety of Lunsekimig in Adults with Inadequately Controlled Eosinophilic COPD
- Evaluation of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Patients
Data & Insights
Has run more than one trial at 120 of 462 partner sites.
Specializations
Chronic Obstructive Pulmonary Disease and exacerbation prevention
Otakar Hokynář is involved in clinical research focused on Chronic Obstructive Pulmonary Disease, with particular attention to reducing exacerbations, improving cardiopulmonary outcomes, and addressing disease control in moderate-to-severe and symptomatic patient populations.
- Severe exacerbation reduction
- Cardiopulmonary outcomes
- Type 2 inflammation
His work in this area spans both established inhaled treatment strategies and newer biologic approaches for persistent COPD burden.
Asthma management in uncontrolled and mild to moderate disease
His research includes asthma care in adults with uncontrolled disease and in patients with mild to moderate asthma, with interest in improving symptom control, lung function, and prevention of asthma events.
- Uncontrolled adult asthma
- Asthma exacerbation prevention
- Forced expiratory volume in 1 second
This area also reflects involvement in evaluating inhaled maintenance therapies and targeted treatments for patients at risk of recurrent respiratory worsening.
Bronchiectasis and pulmonary exacerbations
Otakar Hokynář is active in studies of non-cystic fibrosis bronchiectasis, where the therapeutic focus is on reducing pulmonary exacerbations and improving disease stability in chronic airway disease.
- Non-cystic fibrosis bronchiectasis
- Pulmonary exacerbations
- Chronic airway inflammation
His trial portfolio in this field supports the development of targeted options for patients with recurrent respiratory complications.
Biologic therapies for airway inflammation
His clinical research includes biologic treatment strategies aimed at airway inflammation in COPD, asthma, and bronchiectasis, with emphasis on agents targeting inflammatory pathways linked to exacerbation risk.
- Anti-IL-33 therapy
- Astegolimab
- Depemokimab
This therapeutic domain reflects involvement in innovation for patients whose respiratory disease remains inadequately controlled with conventional inhaled therapy.
Inhaled combination therapy and respiratory function
Otakar Hokynář also contributes to studies of inhaled combination therapy in obstructive lung disease, including evaluation of dual and triple therapy approaches with attention to respiratory function and treatment equivalence in asthma.
- Triple inhaled therapy
- Dual bronchodilator therapy
- Metered-dose inhalers
These interests align with ongoing work in optimizing long-term treatment options for chronic obstructive and asthmatic airway disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.